Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome

Umer Saleem, Mahyar Khaleghi, Nils G. Morgenthaler, Andreas Bergmann, Joachim Struck, Thomas H. Mosley, Iftikhar Jan Kullo

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Context: Stress-mediated hypothalamic-pituitary-adrenal axis activation, regulated by arginine vasopressin (AVP), may have a role in the pathophysiology of metabolic syndrome (MetSyn). Objective: The objective of the study was to investigate whether plasma C-terminal provasopressin fragment (copeptin), a surrogate for circulating AVP, was associated with measures of insulin resistance and presence of MetSyn. Design, Setting, and Participants: This was a multicenter, community-based study, investigating novel biomarkers for vascular disease. Participants included 1293 African-Americans (AA) (64 ± 9 yr) and 1197 non-Hispanic whites (NHW) (59 ± 10 yr) belonging to hypertensive sibships. Main Outcome Measures: Plasma copeptin levels were measured by an immunoluminometric assay. MetSyn was defined per Adult Treatment Panel III criteria. Generalized estimating equations were used to assess whether plasma copeptin was associated with measures of insulin resistance and MetSyn. Results: The prevalence of MetSyn was 50% in AA and 49% in NHW. In each group, after adjustment for age and sex, plasma copeptin levels significantly correlated with body mass index, fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and (inversely) high-density lipoprotein cholesterol (P < 0.05 for each variable). In multivariable logistic regression models that adjusted for age, sex, smoking, statin use, serum creatinine, education, physical activity, and diuretic use, plasma copeptin levels in the highest quartile were associated with an increased odds ratio of having MetSyn compared with bottom quartile: odds ratio (95% confidence interval) in AA, 2.07 (1.45-2.95); in NHW, 1.74 (1.21-2.5). Conclusions: Our findings indicate a novel cross-sectional association between plasma copeptin and measures of insulin resistance and MetSyn.

Original languageEnglish (US)
Pages (from-to)2558-2564
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Insulin Resistance
Insulin
Plasmas
African Americans
Arginine Vasopressin
Logistic Models
Odds Ratio
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Biomarkers
copeptins
Vascular Diseases
Diuretics
HDL Cholesterol
Logistics
Assays
Fasting
Creatinine
Triglycerides
Body Mass Index
Homeostasis

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Plasma carboxy-terminal provasopressin (copeptin) : A novel marker of insulin resistance and metabolic syndrome. / Saleem, Umer; Khaleghi, Mahyar; Morgenthaler, Nils G.; Bergmann, Andreas; Struck, Joachim; Mosley, Thomas H.; Kullo, Iftikhar Jan.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 7, 07.2009, p. 2558-2564.

Research output: Contribution to journalArticle

Saleem, Umer ; Khaleghi, Mahyar ; Morgenthaler, Nils G. ; Bergmann, Andreas ; Struck, Joachim ; Mosley, Thomas H. ; Kullo, Iftikhar Jan. / Plasma carboxy-terminal provasopressin (copeptin) : A novel marker of insulin resistance and metabolic syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 7. pp. 2558-2564.
@article{3709b8cd6a1c4163bed8ee25b530c1e2,
title = "Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome",
abstract = "Context: Stress-mediated hypothalamic-pituitary-adrenal axis activation, regulated by arginine vasopressin (AVP), may have a role in the pathophysiology of metabolic syndrome (MetSyn). Objective: The objective of the study was to investigate whether plasma C-terminal provasopressin fragment (copeptin), a surrogate for circulating AVP, was associated with measures of insulin resistance and presence of MetSyn. Design, Setting, and Participants: This was a multicenter, community-based study, investigating novel biomarkers for vascular disease. Participants included 1293 African-Americans (AA) (64 ± 9 yr) and 1197 non-Hispanic whites (NHW) (59 ± 10 yr) belonging to hypertensive sibships. Main Outcome Measures: Plasma copeptin levels were measured by an immunoluminometric assay. MetSyn was defined per Adult Treatment Panel III criteria. Generalized estimating equations were used to assess whether plasma copeptin was associated with measures of insulin resistance and MetSyn. Results: The prevalence of MetSyn was 50{\%} in AA and 49{\%} in NHW. In each group, after adjustment for age and sex, plasma copeptin levels significantly correlated with body mass index, fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and (inversely) high-density lipoprotein cholesterol (P < 0.05 for each variable). In multivariable logistic regression models that adjusted for age, sex, smoking, statin use, serum creatinine, education, physical activity, and diuretic use, plasma copeptin levels in the highest quartile were associated with an increased odds ratio of having MetSyn compared with bottom quartile: odds ratio (95{\%} confidence interval) in AA, 2.07 (1.45-2.95); in NHW, 1.74 (1.21-2.5). Conclusions: Our findings indicate a novel cross-sectional association between plasma copeptin and measures of insulin resistance and MetSyn.",
author = "Umer Saleem and Mahyar Khaleghi and Morgenthaler, {Nils G.} and Andreas Bergmann and Joachim Struck and Mosley, {Thomas H.} and Kullo, {Iftikhar Jan}",
year = "2009",
month = "7",
doi = "10.1210/jc.2008-2278",
language = "English (US)",
volume = "94",
pages = "2558--2564",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Plasma carboxy-terminal provasopressin (copeptin)

T2 - A novel marker of insulin resistance and metabolic syndrome

AU - Saleem, Umer

AU - Khaleghi, Mahyar

AU - Morgenthaler, Nils G.

AU - Bergmann, Andreas

AU - Struck, Joachim

AU - Mosley, Thomas H.

AU - Kullo, Iftikhar Jan

PY - 2009/7

Y1 - 2009/7

N2 - Context: Stress-mediated hypothalamic-pituitary-adrenal axis activation, regulated by arginine vasopressin (AVP), may have a role in the pathophysiology of metabolic syndrome (MetSyn). Objective: The objective of the study was to investigate whether plasma C-terminal provasopressin fragment (copeptin), a surrogate for circulating AVP, was associated with measures of insulin resistance and presence of MetSyn. Design, Setting, and Participants: This was a multicenter, community-based study, investigating novel biomarkers for vascular disease. Participants included 1293 African-Americans (AA) (64 ± 9 yr) and 1197 non-Hispanic whites (NHW) (59 ± 10 yr) belonging to hypertensive sibships. Main Outcome Measures: Plasma copeptin levels were measured by an immunoluminometric assay. MetSyn was defined per Adult Treatment Panel III criteria. Generalized estimating equations were used to assess whether plasma copeptin was associated with measures of insulin resistance and MetSyn. Results: The prevalence of MetSyn was 50% in AA and 49% in NHW. In each group, after adjustment for age and sex, plasma copeptin levels significantly correlated with body mass index, fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and (inversely) high-density lipoprotein cholesterol (P < 0.05 for each variable). In multivariable logistic regression models that adjusted for age, sex, smoking, statin use, serum creatinine, education, physical activity, and diuretic use, plasma copeptin levels in the highest quartile were associated with an increased odds ratio of having MetSyn compared with bottom quartile: odds ratio (95% confidence interval) in AA, 2.07 (1.45-2.95); in NHW, 1.74 (1.21-2.5). Conclusions: Our findings indicate a novel cross-sectional association between plasma copeptin and measures of insulin resistance and MetSyn.

AB - Context: Stress-mediated hypothalamic-pituitary-adrenal axis activation, regulated by arginine vasopressin (AVP), may have a role in the pathophysiology of metabolic syndrome (MetSyn). Objective: The objective of the study was to investigate whether plasma C-terminal provasopressin fragment (copeptin), a surrogate for circulating AVP, was associated with measures of insulin resistance and presence of MetSyn. Design, Setting, and Participants: This was a multicenter, community-based study, investigating novel biomarkers for vascular disease. Participants included 1293 African-Americans (AA) (64 ± 9 yr) and 1197 non-Hispanic whites (NHW) (59 ± 10 yr) belonging to hypertensive sibships. Main Outcome Measures: Plasma copeptin levels were measured by an immunoluminometric assay. MetSyn was defined per Adult Treatment Panel III criteria. Generalized estimating equations were used to assess whether plasma copeptin was associated with measures of insulin resistance and MetSyn. Results: The prevalence of MetSyn was 50% in AA and 49% in NHW. In each group, after adjustment for age and sex, plasma copeptin levels significantly correlated with body mass index, fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and (inversely) high-density lipoprotein cholesterol (P < 0.05 for each variable). In multivariable logistic regression models that adjusted for age, sex, smoking, statin use, serum creatinine, education, physical activity, and diuretic use, plasma copeptin levels in the highest quartile were associated with an increased odds ratio of having MetSyn compared with bottom quartile: odds ratio (95% confidence interval) in AA, 2.07 (1.45-2.95); in NHW, 1.74 (1.21-2.5). Conclusions: Our findings indicate a novel cross-sectional association between plasma copeptin and measures of insulin resistance and MetSyn.

UR - http://www.scopus.com/inward/record.url?scp=67650257679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650257679&partnerID=8YFLogxK

U2 - 10.1210/jc.2008-2278

DO - 10.1210/jc.2008-2278

M3 - Article

C2 - 19366852

AN - SCOPUS:67650257679

VL - 94

SP - 2558

EP - 2564

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -